Non-traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort  by Baber, U. et al.
Non-traditional risk factors predict coronary
calcification in chronic kidney disease in a
population-based cohort
U Baber1, JA de Lemos2, A Khera2, DK McGuire2, T Omland3, RD Toto4 and SS Hedayati4,5
1Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA; 2Donald W. Reynolds Cardiovascular
Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA; 3Akershus University Hospital, Lorenskog
and University of Oslo, Oslo, Norway, USA; 4Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
and 5Division of Nephrology, Department of Medicine, Veterans Affairs Medical Center, Dallas, Texas, USA
The increased burden of cardiovascular disease in chronic
kidney disease cannot be explained by traditional risk factors
alone. Here, we evaluated the impact of non-traditional
factors on the association of chronic kidney disease with
coronary artery calcification using logistic regression among
2672 Dallas Heart Study patients of whom 220 had chronic
kidney disease. The prevalence of coronary calcification
significantly increased across all chronic kidney disease
stages and this remained independently associated with
coronary calcification after adjusting for traditional factors.
The calciumphosphorus product, homocysteine, and
osteoprotegerin each diminished the magnitude of
association between kidney disease and coronary
calcification. After adjustment for these, the association
between kidney disease and coronary calcification was no
longer significant with the effects most prominent in the
stages 3–5 subgroup. Our study has identified three non-
traditional independent predictors of coronary calcification
that diminished the association between chronic kidney
disease and coronary calcification. These factors may
represent novel mechanistic links warranting further
investigation.
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Excess cardiovascular morbidity and mortality are well-
known complications of end-stage renal disease.1,2 Recent
studies have firmly established that pre-dialysis chronic
kidney disease (CKD) is also independently associated with
incident cardiovascular disease (CVD) and adverse cardio-
vascular outcomes.3–7 Even subjects with mild reductions in
glomerular filtration rate (GFR) of 60–89 ml per min per
1.73 m2 demonstrate a 25% increased risk of developing CVD
relative to those with a GFR490.5 A portion of this elevated
risk may be due to the increased burden of concomitant CVD
risk factors prevalent in patients with CKD, such as
hypertension, diabetes mellitus, and dyslipidemia, factors
that are less well controlled among CKD vs non-CKD
populations.8 However, CKD remains a strong and indepen-
dent predictor of CVD risk even after adjustment for these
traditional factors,3–7 suggesting that the association between
the two disease states may be mediated by non-traditional
CVD risk factors.
Evaluation of non-traditional factors may identify addi-
tional independent predictors of coronary atherosclerosis
that may further attenuate the association between CKD and
CVD and represent novel mechanistic links in the develop-
ment of atherosclerotic disease among patients with CKD.
We analyzed data from a large, multiethnic, probability-based
community cohort to assess the degree to which traditional
and non-traditional risk factors modify the association
between CKD and CVD, using coronary artery calcification
(CAC) as a surrogate marker of coronary atherosclerosis.9–11
RESULTS
Baseline characteristics
The cohort had a mean age of 45.2±9.3 years. Among the
2672 participants, 45.0% were male and 48.8% were African
American. Prevalences of hypertension, diabetes, and hyper-
cholesterolemia were 32.0, 11.3, and 13.4%, respectively. Two
hundred and fifty-two (9.4%) had CAC scores X100 and
2420 (90.6%) had scores o100. CKD prevalence was 19.4%
among those with CACX100 and 7.1% with CACo100
(Po0.0001).
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There were 220 patients with CKD, of whom 170 (77.3%)
had CKD stages 1–2 and 50 (22.7%) had CKD stages 3–5. The
prevalence of CACX100 increased significantly across CKD
stages, from 8.3% in non-CKD patients to 16.5% in patients
with CKD stages 1–2 and 42.0% among those with CKD
stages 3–5 (trend P-valueo0.0001). CKD patients were older,
and a greater proportion was African American and had a
history of diabetes mellitus or hypertension as compared to
those without CKD (Table 1). Across stages of renal
dysfunction, significant increases were observed for levels of
calcium, phosphorus, calcium phosphorous product
(CPP), homocysteine (HCY), C-reactive protein (CRP),
and osteoprotegerin (OPG) (Table 1).
Associations between risk factors and CAC
All traditional and non-traditional factors tested in univari-
able models, with the exception of lipoprotein (a) (Lp (a))
and small low-density lipoprotein (LDL) subclass, were
significantly and positively associated with CACX100
(Table 2). Prevalent CKD was also significantly associated
with CACX100 (odds ratio (OR) 3.18, 95% confidence
interval (95% CI) 2.24–4.50).
Although addition of African-American race and tradi-
tional risk factors to the logistic regression model diminished
the association between CKD and CACX100, CKD remained
significantly associated with CACX100 (OR 1.76, 95% CI
1.16–2.68) (Table 3). Further attenuation was observed in the
association between CKD and CAC after adjustment for
calcium, phosphorus, CPP, HCY, or OPG, whereas CRP did
not markedly influence the association (Table 3). CPP
attenuated the effect of CKD on CAC to a greater degree
than phosphorus or calcium alone and so was included in the
final multivariable model (Table 3). The association between
CKD and CACX100 was no longer statistically significant
once CPP, HCY, and OPG were added together to the final
Table 1 | Clinical and biochemical parameters by CKD stagesa
Independent variables No CKD (n=2452) CKD stages 1–2 (n=170) CKD stages 3–5 (n=50) P-value
Traditional risk factors
Age (years) 44.9±9.3 47.3±9.1 52.5±7.7 o0.0001
Male sex (%) 44.4 54.7 44.0 0.03
African-American race (%) 47.3 67.7 62.0 o0.0001
Family history of myocardial
infarction (%)
32.2 37.1 46.0 0.06
History of smoking (%) 28.2 32.9 38.0 0.14
Diabetes mellitus (%) 9.3 34.7 30.0 o0.0001
Hypertension (%) 29.7 55.9 64.0 o0.0001
Hypercholesterolemia (%) 13.2 14.8 20.0 0.32
Non-traditional risk factors
Homocysteine (mmol l1) 8.8±3.8 10.1±13.3 15.5±7.6 o0.0001
Calcium (mg per 100 ml) 9.3±0.4 9.3±0.4 9.4±0.6 0.0009
Phosphorus (mg per 100 ml) 3.2±0.6 3.2±0.6 3.7±1.0 o0.0001
Calciumphosphorus product
(mg2 per 100 ml2)
29.6±5.4 30.1±6.1 35.2±10.4 o0.0001
C-reactive protein (mg l1) 2.7 (1.1, 6.3) 3.6 (1.6, 7.8) 3.7 (1.8, 9.7) 0.003
Lipoprotein (a) (nmol l1) 47.2 (17.7, 106.8) 54.9 (24.1, 105.0) 62.1 (25.4, 132.1) 0.16
Small LDL subclass (mg per
100 ml cholesterol)
5.6 (0.0, 27.2) 9.8 (0.0, 39.0) 0.0 (0.0, 17.2) 0.02
Osteoprotegerin (pg ml1) 1193.5 (870.5, 1582.1) 1247.2 (943.6, 1892.0) 1420.2 (1015.9, 2272.0) 0.0004
CKD, chronic kidney disease; LDL, low-density lipoprotein.
aContinuous variables with normal distribution are reported as mean±s.d. Continuous variables with non-normal distribution are reported as median (interquartile range).
Categorical variables are reported as percentages.
Table 2 | Univariable logistic models for the associations
between variables and CACX100
Variable OR (95% CI) P-value
Traditional
Age (per year increase) 1.14 (1.12–1.16) o0.0001
Male sex 2.38 (1.82–3.12) o0.0001
African-American race 1.64 (1.26–2.14) o0.0001
Family history of
myocardial infarction
2.12 (1.63–2.75) o0.0001
History of smoking 2.02 (1.55–2.64) o0.0001
Diabetes mellitus 3.30 (2.42–4.51) o0.0001
Hypertension 4.48 (3.41–5.88) o0.0001
Hypercholesterolemia 3.24 (2.41–4.37) o0.0001
Non-traditional
Chronic kidney disease 3.18 (2.24–4.50) o0.0001
Homocysteine (mmol l1)a 1.06 (1.03–1.08) o0.0001
Calcium (mg per 100 ml)a 2.31 (1.62–3.30) o0.0001
Phosphorus (mg per
100 ml)a
1.33 (1.08–1.65) 0.0092
Calciumphosphorus
product (mg2 per
100 ml2)a
1.05 (1.03–1.07) o0.0001
Log C-reactive proteina 1.19 (1.06–1.33) 0.002
Lp (a) tertile 2 vs 1b 1.55 (1.03–2.33) 0.09
Lp (a) tertile 3 vs 1b 1.89 (0.55–6.54) 0.09
Small LDL tertile 2 vs 1b 1.21 (0.79–1.85) 0.37
Small LDL tertile 3 vs 1b 1.98 (0.67–5.85) 0.37
Log osteoprotegerina 1.97 (1.56–2.49) o0.0001
CAC, coronary artery calcification; CI, confidence interval; LDL, low-density
lipoprotein; Lp (a), lipoprotein (a); OR, odds ratio.
aPer unit increase.
bTertile 1 represents lowest tertile and tertile 3 represents highest tertile.
616 Kidney International (2008) 73, 615–621
o r i g i n a l a r t i c l e U Baber et al.: CKD and coronary calcification
multivariable model containing the traditional risk factors
(OR 1.41, 95% CI 0.91–2.18).
Stratification by CKD stages
Univariable and multivariable analyses were repeated after
stratifying the population by CKD stages (Table 4). In the
univariable analyses, CKD stages 1–2 and CKD stages 3–5 (vs
no CKD) were both significantly associated with CACX100,
with a larger point estimate of association observed for CKD
stages 3–5 (OR 8.02, 95% CI 4.49–14.32) as compared with
CKD stages 1–2 (OR 2.19, 95% CI 1.42–3.36).
In multivariable analyses, the association between CKD
stages 1–2 and CACX100 was completely attenuated with the
inclusion of African-American race and traditional risk
factors, whereas only partial attenuation was observed for
CKD stages 3–5, which remained an independent predictor of
CAC (Table 4). Calcium, phosphorus, CPP, HCY, and OPG
each separately further attenuated the association between
CKD stages 3–5 and CACX100, whereas CRP did not
(Table 4). Similar to the non-stratified analysis (Table 3),
CPP attenuated the effect of CKD on CAC to a greater degree
than phosphorus or calcium alone and so was included in the
final multivariable model (Table 4). After CPP, HCY, and
OPG were entered together into the final multivariable
model, the association between CKD stages 3–5 and
CAC4100 was attenuated but remained statistically signi-
ficant (OR 2.38, 95% CI 1.15–4.95).
Sensitivity analysis using a CAC cut-off of X30 instead of
X100 for logistic models revealed similar results and did not
change the main findings of this study. The overall accuracy
of the logistic models using CACX30 was also similar to the
models using CACX100 (c-statistic of 0.86 and 0.87,
respectively). Sensitivity analysis performed excluding seven
patients who responded ‘yes’ to the question ‘do you have or
have you ever had chronic kidney failure requiring dialysis’
decreased the magnitude of association between any CKD
and CAC and attenuated the association of CKD stages 3–5
with CAC once all non-traditional factors were entered into
the final model (OR 1.88, 95% CI 0.85–4.14).
DISCUSSION
The principal new finding in this study is that the non-
traditional risk factors CPP, OPG and HCY diminished the
association between CKD and clinically relevant CAC. This
finding suggests that pathways represented by these markers
(such as vascular calcification, endothelial injury, and
accelerated thrombosis) may contribute to the excess burden
of coronary artery disease observed in patients with CKD.
Furthermore, the attenuation of the association between
CKD and CAC observed with these non-traditional factors
appeared to be stronger at advanced stages of CKD vs earlier
stages, whereas traditional risk factors appear to exert their
effect at both CKD stages. This important new finding in a
relatively young, multiethnic cohort extends previous find-
ings from studies performed in older populations.12–16 An
alternative explanation is that our cohort is relatively young,
and thus contributions from traditional risk factors may be of
a lesser degree than in older CKD populations. The enhanced
effect of non-traditional risk factors at more advanced (vs
milder) stages of CKD is biologically plausible, as the
metabolic and hemodynamic alterations associated with
CKD progress as GFR declines and may provide the proper
milieu for the development of accelerated atherosclerosis.
Elevations in serum parathyroid hormone, for example, do
not occur until GFR decreases below 70 ml per min per
Table 3 | Multivariable logistic models for the association
between CKD and CACX100
Model CKD OR (95% CI) C-statistic
1. CKD alone 3.18 (2.24–4.50) 0.562
2. CKD+traditional factorsa 1.76 (1.16–2.68) 0.867
3. Model 2+calcium 1.71 (1.12–2.60) 0.868
4. Model 2+phosphorus 1.67 (1.09–2.54) 0.869
5. Model 2+CPP 1.62 (1.06–2.48) 0.871
6. Model 2+homocysteine 1.56 (1.01–2.39) 0.867
7. Model 2+log osteoprotegerin 1.67 (1.10–2.55) 0.869
8. Model 2+log C-reactive protein 1.77 (1.16–2.70) 0.866
9. Model 2+CPP, HCY, log OPG 1.41 (0.91–2.18) 0.873
CAC, coronary artery calcification; CKD, chronic kidney disease; CI, confidence
interval; CPP, calcium phosphorous product; HCY, homocysteine; OR, odds ratio;
OPG, osteoprotegerin.
aCovariates included were age, male gender, family history of myocardial infarct,
history of smoking, diabetes mellitus, hypertension, and hypercholesterolemia, in
addition to African-American race.
Table 4 | Multivariable logistic models for CACX100 stratified by CKD stages
Model CKD stages 1–2a CKD stages 3–5a C-statistic
1. CKD alone 2.19 (1.42–3.36) 8.02 (4.49–14.32) 0.564
2. CKD+traditional factorsb 1.16 (0.69–1.93) 4.31 (2.20–8.43) 0.870
3. Model 2+calcium 1.12 (0.67–1.89) 4.11 (2.10–8.05) 0.870
4. Model 2+phosphorus 1.16 (0.69–1.94) 3.60 (1.82–7.13) 0.870
5. Model 2+CPP 1.16 (0.69–1.94) 3.33 (1.68–6.62) 0.873
6. Model 2+homocysteine 1.14 (0.68–1.92) 3.12 (1.53–6.34) 0.869
7. Model 2+log osteoprotegerin 1.12 (0.67–1.87) 3.91 (1.99–7.70) 0.872
8. Model 2+log C-reactive protein 1.17 (0.70–1.95) 4.30 (2.20–8.42) 0.869
9. Model 2+CPP, HCY, log OPG 1.12 (0.67–1.89) 2.38 (1.15–4.95) 0.874
CAC, coronary artery calcification; CKD, chronic kidney disease; CPP, calcium phosphorous product; HCY, homocysteine; OPG, osteoprotegerin.
aOdds ratios are for CKD stages 1–2 vs no CKD and CKD stages 3–5 vs no CKD.
bCovariates included were age, male gender, family history of myocardial infarct, history of smoking, diabetes mellitus, hypertension, and hypercholesterolemia, in addition to
African-American race.
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1.73m2,17 and mean serum phosphorus levels do not increase
rapidly until GFR declines to below 40 ml per min per
1.73 m2.18
In contrast to most previous studies that involved CKD
patients on chronic dialysis, our study evaluating the
relationship between calcium, phosphorus, CPP, and CAC
involved patients with earlier stages of CKD. Only 7 of 2672
had been or were currently on hemodialysis, and the
exclusion of those patients did not alter the results
considerably except that, as expected, it decreased the
magnitude of the association between CKD and CAC.
Although elevated CPP has been reported to be an
independent predictor of mortality in dialysis patients,19
studies evaluating the relationship between various indices of
calcium/phosphorus homeostasis and CAC in pre-dialysis
CKD patients have generated inconsistent results.12–16,20,21 In
fact, the National Kidney Foundation guidelines regarding
management of calcium/phosphorus homeostasis, such as
desired parathyroid hormone levels, are opinion based rather
than evidence based for pre-dialysis stages 3 and 4 CKD.17
Two earlier studies reported a positive association between
serum phosphorus levels and CAC or CAC progression in
such patients.16,20 A graded independent relationship be-
tween higher levels of serum phosphorus and risk of death
and cardiovascular events was reported in patients with
previous myocardial infarct, most of whom had phosphorus
levels within the normal range.22 Our results extend these
observations as we found that calcium, phosphorus, and CPP
were all positively associated with CAC, and each diminished
the association between CKD and CAC in multivariable
models, with CPP causing the greatest attenuation. The
c-statistics of the multivariable models for CAC were
the same when either calcium or phosphorus was included
in separate models (both 0.87), indicating that both variables
are similarly contributing to the model fit. More importantly,
this effect was observed in a population with mean CPP levels
of 35.2 mg2 per 100 ml2, well below the level of 55 mg2 per
100 ml2 previously associated with increased cardiovascular
risk in chronic dialysis patients.19 This suggests that even the
modest perturbations in calcium/phosphorus metabolism
observed in patients with earlier stages of CKD may
contribute to coronary calcification. Large prospective
interventional trials are needed to investigate whether more
aggressive control of CPP in the pre-dialysis phase of CKD
may decrease future risk of CVD.
We found that HCY had a modest impact on the
association between CKD stages 3–5 and CAC. Although
levels of HCY are elevated among pre-dialysis CKD vs non-
CKD patients,23,24 less is known regarding the CVD risk
associated with hyperhomocysteinemia in such subjects. Five
previous studies examining the relationship between CKD
and CAC did not include HCY as a covariate.12–16 Two other
studies, however, demonstrated an association between HCY
and cardiovascular events in either pre-dialysis CKD or
kidney transplant recipients.25,26 Our results are consistent
with these latter observations and suggest that the increased
CVD risk conferred by HCY in dialysis patients27,28 may
begin in the pre-dialysis disease phase and may be due to its
contribution to coronary atherosclerosis burden.29,30 It
should be noted, unfortunately, that the excess risk
attributable to HCY in patients with advanced CKD may
not be modifiable with folic acid and vitamin B therapy.31
OPG diminished the association between CKD stages 3–5
and CAC scores X100, suggesting that OPG may contribute
to the increased risk of CVD observed in these patients. OPG
functions as a regulator of bone resorption by inhibiting
osteoclastogenesis.32 The mechanisms responsible for the
observed association between OPG and arterial calcification
remain poorly understood and appear paradoxical. For
example, OPG-deficient mice develop widespread arterial
calcifications,33 whereas serum OPG levels are higher in
subjects with greater amounts of coronary calcification.34–37
In fact, a U-shaped association between OPG and all-cause
mortality has been described in hemodialysis patients in the
presence of inflammation.38 One potential hypothesis is that
OPG expression increases in the setting of pre-existing
calcification and acts in a compensatory manner to minimize
further calcification. Another explanation is that OPG
directly contributes to vascular calcification by promoting a
low bone turnover state.39 In this context, the ability of bone
to take up a mineral load is diminished,40 which might favor
extra-skeletal calcification. Studies involving CKD patients,
however, have been limited either to those with stage 5 CKD
before and after dialysis initiation or to renal transplant
recipients. Our findings extend these observations by
suggesting that OPG may promote coronary calcification in
earlier CKD stages and could possibly serve as a biomarker to
assess CVD risk among pre-dialysis CKD patients.
Despite the established association between various non-
traditional risk factors (such as anemia, measures of
inflammation, and calcium/phosphorus homeostasis) and
poor cardiovascular outcomes in dialysis patients, there are
few data regarding such factors in patients with pre-dialysis
CKD. Our results suggest that novel pathways represented by
HCY, CPP, and OPG may promote CVD in patients with
moderate to severe pre-dialysis CKD. If validated using other
measures of atherosclerosis and in cohort studies with
adequate numbers of clinical events, these findings could
have important clinical and therapeutic implications. These
novel factors may assist in risk assessment of patients with
CKD, to determine which are at highest risk for adverse CV
events and require the most aggressive preventive therapies.
Alternatively, if these factors are causally related to CVD in
patients with CKD, they may serve as therapeutic targets. For
example, the CPP target for treatment may need to be
lowered in stages 3–5 pre-dialysis CKD.18 Therapies targeting
receptor activator of nuclear factor-kB (RANK) and RANK
ligand may merit investigation as targets for CVD prevention
in patients with CKD.38 Larger, prospective studies are
needed to determine whether these non-traditional factors
play a critical role in development of CVD, and interven-
tional trials are required to investigate whether modification
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of these factors may decrease cardiovascular morbidity and
mortality.
Our study is not without limitation and due to its cross-
sectional nature cannot imply a causal relationship between
non-traditional risk factors and CAC. Biochemical para-
meters, including urine microalbumin, were measured once
and might not reflect actual levels over time. In addition, we
were unable to adjust for certain confounders, such as intact
parathyroid hormone, anemia, and fibrinogen, that are
associated with either CAC or CVD risk among CKD
patients. Although we controlled for diabetes in all of the
multivariable models, diabetics comprised only 30% of the
subgroup with CKD, and therefore these findings should be
confirmed in populations with a greater proportion of
diabetic nephropathy. We evaluated a limited number of
non-traditional cardiovascular risk markers that were avail-
able in the Dallas Heart Study database and did not evaluate
several others, such as asymmetric dimethyl arginine
(ADMA)41 and fetuin A,42 that have shown promise in
patients with CKD. Even though using a CAC scoreX100 as
our main outcome measure makes our findings more
clinically relevant, coronary calcification is only a surrogate
marker of cardiovascular outcomes among patients with
preserved renal function.9–11 Less is known regarding the
relationship between CAC and outcomes in CKD, although
CAC scores were associated with clinically evident coronary
artery disease among pre-dialysis CKD patients.12
Conclusions
We found that non-traditional cardiovascular risk factors
diminished the association between clinically relevant
CAC and CKD. This effect was strongest and most consistent
in those with more advanced CKD. Non-traditional factors
such as increased CPP, HCY, and OPG are more prevalent
in CKD vs non-CKD populations and might partially
explain the excessive cardiovascular morbidity and mortality
in CKD patients. Future prospective studies are necessary
to investigate the potential mechanistic relationships
between non-traditional risk factors and CKD and to
determine whether modifying such risk factors will improve
outcomes.
MATERIALS AND METHODS
Study population
The Dallas Heart Study is a cross-sectional cohort study comprising
a multiethnic, population-based, probability sample of Dallas
County residents aged 30–65 years. The study design has been
described previously.43 After an initial in-home visit to obtain
demographic and health-related data (n¼ 6101), a second in-home
visit was performed where fasting venous blood and urine samples
were collected (n¼ 3557), and a third visit to University of Texas
Southwestern Medical Center where comprehensive imaging studies
were obtained, including electron beam computed tomography
(EBCT) scanning of the coronary arteries (n¼ 2971). Our analyses
were restricted to the 2672 patients in whom there were sufficient
data for estimations of GFR, urine microalbumin, and EBCT
assessment of CAC.
Evaluation of kidney function
The urinary albumin/creatinine ratio (ACR) was calculated using a
first morning void sample. GFR (ml per min per 1.73 m2 body
surface area) was estimated with the four-variable Modification of
Diet in Renal Disease (MDRD) Study formula using the serum
creatinine measurement: GFR¼ 186 (serum creatinine1.154)
 (age0.203) (0.742 if female) (1.21 if black).44 Using the
National Kidney Foundation guidelines, CKD stages 1–2 were
defined as an albumin/creatinine ratio (mg g1) X17 in men and
X25 in women and a GFRX60 ml per min per 1.73 m2 body surface
area, and CKD stages 3–5 were defined as an estimated GFR o60.45
Evaluation of CAC
EBCT measurements were made at 80% of the RR interval using an
Imatron 150 XP (Imatron Inc., San Francisco, CA, USA), 30 cm field
of view, 512 matrix with sharp kernel reconstruction, and scores
were expressed in Agatston units.46 Calcium scoring followed the
Multi Ethnic Study of Atherosclerosis (MESA) protocol.47 The mean
of two consecutive scans was used as the final EBCT score except in
subjects in whom only one scan was obtained. A CAC score ofX100
was used to define clinically relevant CAC, as this cut-off
corresponds to moderate to high 10-year risk of cardiovascular
events.9,48–52
Clinical covariates
Race was dichotomized as African American or non-African
American according to the subject’s self-report. Five consecutive
blood pressure (BP) readings were recorded at 1-min intervals, and
the average of the third, fourth, and fifth measurements was used for
analysis. Hypertension was defined as self-reported diagnosis or
treatment for hypertension or a systolic BPX140 mm Hg or a
diastolic BPX90 mm Hg. Diabetes definition was based on a self-
report coupled with use of insulin or oral hypoglycemic medication;
a fasting glucoseX126 mg per 100 ml or a non-fasting glucoseX
200 mg per 100 ml. Hypercholesterolemia was defined as a fasting
calculated LDL cholesterolX160 mg per 100 ml, direct LDLX
160 mg per 100 ml on a non-fasting sample, total cholesterolX
240 mg per 100 ml, or the use of statin medication. Family history of
heart attack was self-reported and defined as history of heart attack
in a first-degree relative (mother, father, sibling, or child). Smoking
was defined as cigarette use within the previous 30 days and a
lifetime history of having smokedX100 cigarettes.
Blood samples were maintained at 4 1C until the plasma
separated and placed in aliquots that were stored at 80 1C. Plasma
Lp (a) was measured by a sandwich ELISA (enzyme-linked
immunosorbent assay) that is insensitive to apolipoprotein(a)
isoform size.53 Lipoprotein subclass profiles were measured on
plasma samples by a commercially available proton NMR (nuclear
magnetic resonance) spectroscopic assay (LipoScience, Raleigh, NC,
USA) as described previously.54,55 The NMR method provides a
direct measure of a given lipoprotein subclass. The small LDL
subclass includes those particles ranging in size from 18.3 to 19.7 nm
with a concentration reported in mass units of cholesterol (mg per
100 ml cholesterol). OPG measurements were performed in
duplicate on thawed samples by an enzyme-linked immunoassay
(R&D systems, Minneapolis, MN, USA).56 The sensitivity of this
assay, defined as the mean±3 s.d. of the zero standard, was
calculated to be 15 pg ml1. CRP measurements were performed
using a commercially available high-sensitivity assay (Roche
Diagnostics, Indianapolis, IN, USA).57 HCY was measured by
LipoScience laboratory using chemiluminescence immunoassay
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(DPC Immulite, Holliston, MA, USA). CPP was defined as the
product of the serum calcium concentration and the serum
phosphorus concentration in mg2 per 100 ml2.
Statistical analysis
Categorical data are reported as percentages and continuous data as
means±s.d. or medians with interquartile ranges. Comparisons
were made across three groups based on CKD stages: no CKD, CKD
stages 1–2, and CKD stages 3–5. Variables were compared between
groups using the w2 test for categorical data. For continuous
variables, one-way analysis of variance was used to compare those
with Gaussian distributions, and Kruskal–Wallis test was used for
those with non-Gaussian distributions.
Two sets of logistic regression models were constructed with
CACX100 as the dependent variable. In the first set, prevalent CKD
was the main independent variable and was dichotomized as CKD
presence vs no CKD. In the second set, CKD (as the main
independent variable) was trichotomized into no CKD, CKD stages
1–2, and CKD stages 3–5, with no CKD as the referent group.
Associations between the following variables and CACX100 were
tested in univariable logistic regression: African-American race and
traditional risk factors, which included age, male sex, family history
of myocardial infarction (MI), history of smoking, hypertension,
diabetes mellitus, and hypercholesterolemia; and non-traditional
factors, which included calcium, phosphorus, CPP, HCY, CRP, Lp
(a), small LDL, and OPG. Owing to non-Gaussian distributions,
OPG and CRP were log-transformed, whereas small LDL and Lp (a)
were divided into tertiles. Only those covariates that had a P-value
o0.05 in univariable models were tested as candidate variables in
the multivariable logistic regression models. Calcium, phosphorus,
and CPP were separately tested in multivariable models and were
not included in the same models concurrently due to concerns for
multicollinearity.
To test that choosing a higher but more specific CAC cut-off of
X100 does not miss a number of subjects at considerable risk, we
performed a sensitivity analysis using a CAC cut-off of X30 for
logistic models. All statistical tests were two-sided, conducted at the
standard significance level of 0.05 and reported using P-values and/
or 95% CIs. All analyses were performed using SAS Enterprise Guide
Version 3.0 and SAS software Version 9.1 (Cary, NC, USA).
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